U.S. Markets close in 3 mins

BioTelemetry (NASDAQ:BEAT) Shareholders Have Enjoyed A Whopping 538% Share Price Gain

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

It might be of some concern to shareholders to see the BioTelemetry, Inc. (NASDAQ:BEAT) share price down 15% in the last month. But that doesn't undermine the fantastic longer term performance (measured over five years). Indeed, the share price is up a whopping 538% in that time. So it might be that some shareholders are taking profits after good performance. But the real question is whether the business fundamentals can improve over the long term.

Anyone who held for that rewarding ride would probably be keen to talk about it.

See our latest analysis for BioTelemetry

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During the last half decade, BioTelemetry became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains. Since the company was unprofitable five years ago, but not three years ago, it's worth taking a look at the returns in the last three years, too. We can see that the BioTelemetry share price is up 446% in the last three years. During the same period, EPS grew by 68% each year. That makes the EPS growth rather close to the annualized share price gain of 76% over the same period. So you could reasonably conclude that investor sentiment towards the stock has remained pretty steady, over time. Rather, the share price has approximately tracked EPS growth.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:BEAT Past and Future Earnings, April 1st 2019

It is of course excellent to see how BioTelemetry has grown profits over the years, but the future is more important for shareholders. This free interactive report on BioTelemetry's balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

We're pleased to report that BioTelemetry shareholders have received a total shareholder return of 104% over one year. That gain is better than the annual TSR over five years, which is 45%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Before deciding if you like the current share price, check how BioTelemetry scores on these 3 valuation metrics.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.